ARTICLE | Clinical News
Tonmya: Phase III data
September 12, 2016 7:00 AM UTC
Top-line data from the double-blind, U.S. Phase III AFFIRM trial in 519 fibromyalgia patients showed that once-daily 2.8 mg sublingual TNX-102 missed the primary endpoint of a greater proportion of pa...